Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1/2 9Phase 1 4Phase 3 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × tafasitamab × Lymphoid × Clear all
NCT05429268 2026-05-05

firmMIND

Incyte Corporation

Phase 3 Active not recruiting
82 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

Incyte Corporation

Phase 3 Active not recruiting
899 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡